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Abstract
A major therapeutic challenge is how to replace bone once it is lost. Bone loss is a characteristic of chronic inflammatory
and degenerative diseases such as rheumatoid arthritis and osteoporosis. Cells and cytokines of the immune system are
known to regulate bone turnover by controlling the differentiation and activity of osteoclasts, the bone resorbing cells.
However, less is known about the regulation of osteoblasts (OB), the bone forming cells. This study aimed to investigate
whether immune cells also regulate OB differentiation. Using in vitro cell cultures of human bone marrow-derived
mesenchymal stem cells (MSC), it was shown that monocytes/macrophages potently induced MSC differentiation into OBs.
This was evident by increased alkaline phosphatase (ALP) after 7 days and the formation of mineralised bone nodules at 21
days. This monocyte-induced osteogenic effect was mediated by cell contact with MSCs leading to the production of
soluble factor(s) by the monocytes. As a consequence of these interactions we observed a rapid activation of STAT3 in the
MSCs. Gene profiling of STAT3 constitutively active (STAT3C) infected MSCs using Illumina whole human genome arrays
showed that Runx2 and ALP were up-regulated whilst DKK1 was down-regulated in response to STAT3 signalling. STAT3C
also led to the up-regulation of the oncostatin M (OSM) and LIF receptors. In the co-cultures, OSM that was produced by
monocytes activated STAT3 in MSCs, and neutralising antibodies to OSM reduced ALP by 50%. These data indicate that
OSM, in conjunction with other mediators, can drive MSC differentiation into OB. This study establishes a role for monocyte/
macrophages as critical regulators of osteogenic differentiation via OSM production and the induction of STAT3 signalling in
MSCs. Inducing the local activation of STAT3 in bone cells may be a valuable tool to increase bone formation in osteoporosis
and arthritis, and in localised bone remodelling during fracture repair.
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Introduction
Fragility fractures as a consequence of osteoporosis, as well as
bone loss associated with chronic inflammatory diseases such as
inflammatory arthritis, are extremely common and represent
major unmet clinical problems. Over 200 million people suffer
from osteoporosis worldwide, and 9 million fragility fractures
occur every year [1], with the most severe often resulting in
permanent disability and increased mortality rates. To reduce the
socioeconomic impact of these common clinical conditions, it is
imperative that ways to promote bone formation are discovered.
However, treatment options remain inadequate or non-existent.
Although the inhibition of bone resorbing osteoclasts (OCs) using
drugs such as bisphosphonates, calcitonin and selective estrogen
receptor modulators will prevent further bone loss, these agents
do not stimulate new bone formation. In terms of bone anabolic
factors, parathyroid hormone increases bone mass when admin-
istered intermittently but can only be given to patients for a
limited number of years. Strontium ranelate has also been shown
to have bone anabolic effects but it is only approved for use in
Europe [2]. In fracture repair, recombinant forms of bone
morphogenetic protein 2 (BMP2) and BMP7 have been given
locally, but cannot be used systemically and their efficacy has not
been proven as animal models would have indicated [3,4]. Anti-
sclerostin antibodies have shown early promise but are currently
limited to systemic use and face potential safety issues, including
carcinogenesis [5]. Thus, there is a significant unmet need for the
identification and characterization of novel bone anabolic agents.
Understanding the molecular and cellular details of the
pathways that control bone formation is critical for the
discovery of new bone anabolics. Osteoblasts (OB) are derived
from mesenchymal stem cells (MSC), a type of adult stem cell
that resides in the bone marrow [6,7,8]. Osteogenic differen-
tiation of MSCs is under the control of OB-specific transcription
factors such as Runx2 and Osterix [9,10,11], as well as
numerous secreted factors of paracrine, autocrine, and endo-
crine origin. These include certain BMPs, PTH, FGF, IGF,
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endothelin-1, and prostaglandin agonists [12,13,14]. Canonical
Wnt signalling also regulates OB differentiation [15,16] and
cooperates with Runx2 and Osterix to maintain and promote
OB maturation. Dickkopf-1 (Dkk1) and sclerostin, an exclusively
osteocyte-derived inhibitor of osteoblastogenesis, have been
shown to block Wnt signaling [17,18]. Dkk1-specific antibodies
reversed bone destruction in a mouse model of rheumatoid
arthritis [19], while antibodies to sclerostin are currently under
investigation for the treatment of osteoporosis and fracture
healing in clinical trials [20].
Whilst these current bone anabolic agents target known
pathways associated with OB differentiation, a novel approach
would be to exploit the more recent understanding of the
regulatory role of the immune system in bone biology. Since the
early observations that persistence of inflammation leads to bone
loss, multiple immune components including T cells, B cells and
various cytokines, have been shown to regulate the OCs and OBs
[21,22,23,24]. More recently, it has been shown that resident
macrophages, termed OsteoMacs, are intercalated within murine
and human osteal tissues and are required for osteogenesis [25].
These macrophages are intimately associated with regions of bone
modeling in situ whilst their depletion caused a complete loss of the
OB bone-forming surface at this modeling site. The same authors
have also shown that macrophages are involved in intramembra-
nous fracture repair [26]. These findings suggest that macrophages
can regulate both the differentiation and mineralization of OBs
but the mechanisms and mediators governing these interactions
remain unknown.
Various aspects of the interactions between MSCs and
immune cells have been investigated at length, particularly
those involved in the regulatory role of MSCs on haematopoi-
esis in the bone marrow niche [27,28,29], as well as those
involved in conferring the immunosuppressive properties of
MSCs. Several groups have suggested that the molecular
mechanisms involved in the latter require both cell-cell
interactions as well as soluble factors [30,31,32,33] including
interleukin-10 (IL-10) [34], IL-1b and TGFb [35], IFNc and
TNFa [36] and PGE2 [37,38]. All of these studies have focused
on the ability of MSCs to limit the proliferation of immune
cells; however these relationships are likely to be reciprocal and
the influence of immune cells on MSC lineage commitment,
and hence the skeletal system are largely unreported. We
hypothesized that the mechanisms and factors involved in
immune suppression also affects MSC differentiation and/or
function. Indeed, IL-1b and TGFb have been shown to
promote the osteogenic differentiation of MSCs [39,40].
We report here that monocyte/macrophages can directly
promote MSC osteogenic differentiation through cell contact
interactions, thus resulting in the production of osteogenic factors
by the monocytes. This mechanism is mediated by the activation
of STAT3 signaling pathway in the MSCs that leads to the up-
regulation of OB-associated genes such as Runx2 and alkaline
phosphatase (ALP), and the down-regulation of inhibitors such as
DKK1 to drive the differentiation of MSCs into OBs. Addition-
ally, the up-regulation of Oncostatin (OSM) receptor (OSMR) and
Leukemia Inhibitory Factor receptor (LIFR) following STAT3
activation in MSCs, indicated OSM as a key monocyte-derived
osteogenic factor acting to enhance osteogenic differentiation via
the STAT3 signaling pathway. These findings further our
understanding of cellular interactions underlying bone formation
to provide therapeutic targets for the next generation of bone
anabolic factors.
Results
Monocytes are Potent Inducers of Osteogenic
Differentiation
To ascertain the effect of immune cells on OB differentiation,
co-cultures of human MSCs and peripheral blood mononuclear
cells (PBMCs) isolated from healthy human donors were
established at increasing ratios of PBMC:MSC. ALP staining
and quantification of enzyme activity revealed that co-culture in
osteogenic medium resulted in a dose dependent increase in ALP-
positive cells as compared to mono-cultures of MSCs (Figure 1A
and 1C). Likewise, ALP activity was significantly elevated in co-
cultures in control medium compared to MSCs alone although the
magnitude was lower than that observed in the presence of
osteogenic medium (Figure 1A and 1C). The ability of PBMCs to
induce osteogenesis was confirmed in bone nodule formation
assays, as visualized by alizarin red S staining, and occurred
exclusively in osteogenic medium (Figure 1B and 1D), indicating
that PBMC-derived signals synergize with, but do not replace,
osteogenic signals generated by the differentiation medium. These
data show that PBMCs can promote MSC to OB differentiation.
To identify the population within the PBMCs responsible for this
osteogenic effect, T cells, B cells and monocytes were systemat-
ically depleted from PBMCs and the depleted populations co-
cultured with MSCs at the ratio of 10:1. Depletion of monocytes
led to a 5-fold decrease in PBMC-mediated ALP induction in
MSCs (Figure 1E), indicating that monocytes are responsible for
the elevated MSC-ALP activity. The contribution of monocytes to
increasing MSC-ALP activity was further verified using enriched
T cell, B cell and monocyte populations in MSC co-cultures. The
addition of enriched T cell and B cell populations did not have any
effect on basal MSC ALP activity of mono-culture controls, thus
indicating that neither T cells nor B cells could promote or inhibit
MSC differentiation in their resting state (Figure 1F). However, in
the presence of monocyte-enriched populations there was a
significant increase in MSC-ALP activity (3-fold as compared to
control) (Figure 1F). In the presence of monocyte-enriched
populations, increased bone nodule formation was also observed
(Figure 1G and 1H). To determine whether differentiated myeloid
cells also support osteogenesis, monocytes were differentiated to
macrophages for 5 days using either M-CSF or GM-CSF prior to
co-culture with MSCs. As shown in Figure 1I, both cell types
induced MSC differentiation, indicating that cells of the monocytic
lineage are capable of producing osteo-inductive factors.
Monocyte-derived Soluble Factors Promote OB
Differentiation and Signaling in MSCs
The ability of monocytes to promote osteogenic differentiation
of MSCs was found to require cell contact because the separation
of the two cell types using 0.4 mM pore size semi-permeable
transwells significantly abrogated the increase in ALP staining and
activity seen in the co-cultures in contact (Figure 2A and B).
However, co-culturing MSCs and monocytes in the upper
chambers of the transwells was sufficient to induce an increase
in ALP staining and activity of MSCs cultured alone in the lower
chamber of the transwells, indicating that cell contact leads to the
production of soluble mediator(s) that are able to induce
osteogenesis (Figure 2A and B). Indeed, conditioned media
obtained from 10:1 monocyte/MSC overnight co-cultures in-
creased ALP activity when added to MSCs alone (Figure 2C).
Soluble factors responsible for MSC osteogenesis were monocyte-
derived as fixing monocytes prior to co-culture with MSCs
abrogated ALP induction (Figure 2D). The addition of co-culture
supernatant to MSCs alone cultures showed that monocyte-
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derived factors led to the activation of various signaling pathways
as shown by IkBa degradation, increased phosphorylation of the
MAPKs; p-38, ERK and JNK, and STAT3 within 30 minutes
(Figure 2E). Supernatants from co-cultures of MSCs and fixed
monocytes that failed to induce MSC differentiation (Figure 2D)
also failed to activate any of these signaling pathways (Figure 2E).
Conversely, fixing the MSCs prior to co-culture with monocytes
did not inhibit signaling in response to the supernatants showing
that contact with the cell surface of MSCs is sufficient to induce
the production of monocyte-derived factors necessary for cell
Figure 1. Monocytes potently induce osteogenic differentiation of MSCs. 16104 MSCs were cultured either alone or with increasing
numbers of PBMCs (1,2,5 or 106105 PBMCs), in the presence or absence of osteogenic stimuli. After 7 days, MSC ALP was assessed by staining (A) and
after 21 days, bone nodule formation was visualised by Alizarin Red S staining (B). ALP activity (C) and Alizarin Red content (D) were also quantified.
Populations of T cells, B cells or monocytes within PBMCs were either depleted (E) or enriched (F) prior to culture with MSC (at 10:1 ratio) and ALP
activity was quantified after 7 days. Co-cultures of MSCs with enriched monocyte populations were also kept for 21 days in osteogenic media when
bone nodule formation was assessed using Alizarin Red S staining (G) and quantification of dye content (H). Monocytes were differentiated to
macrophages (Mw) in either M-CSF or GM-CSF for 5 days prior to co-culture with MSCs at a ratio of 10:1. After 7 days of co-culture, ALP activity was
quantified (I). Phase contrast pictures (10X) are representative of three independent experiments performed. Graphs show means 6 SEM of three
independent experiments performed in triplicates. *p#0.05, **p#0.01, ***p#0.001.
doi:10.1371/journal.pone.0039871.g001
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signaling in the MSCs (Figure 2E). ELISA of the co-culture
supernatants identified elevated cytokines in the media including
IL-1b, IL-10, TNFa, IL-6 and IL-8 (Figure 2F). Of these cytokines
only IL-1b could increase ALP activity when added directly to
MSC cultures in increasing concentrations (Figure S1A). However,
addition of IL-1b neutralising antibody failed to abrogate the
monocyte-induced ALP activity in MSC indicating that it is not
the mediator of monocytes’ osteogenic activity (Figure S1B).
Addition of IL-10, IL-6 and IL-8 (Figure S1D, E, G) had no direct
effect on MSC-ALP activity whilst TNFa was inhibitory at high
concentrations (.10 ng/ml) (Figure S1C). In addition to a lack of
effect on ALP activity, IL-10 and IL-6 did not cause STAT3
phosphorylation in MSCs in contrast to the 10:1 co-culture
supernatant (Figure S1F, 1H). Thus, despite being well known
activators of the STAT3 signalling pathway, IL-6 and IL-10 were
not responsible for the STAT3 activation observed in monocyte/
MSC co-cultures.
Likewise, BMP2, BMP4 and BMP7 and TGFb1 levels were not
elevated in co-culture conditioned media (Table S1). Furthermore,
neutralisation of BMP2, 3, 4, 7 and TGFb1 in these co-cultures
did not inhibit the ability of macrophages to induce MSC ALP
activity indicating that these factors are not mediators of the
monocyte/macrophage-mediated osteogenic induction (Figure
S2).
STAT3 Activation Promotes Osteoblast Differentiation
Investigations into the signaling pathways regulating OB
differentiation and function have tended to focus on factors that
are downstream of BMP, Wnt, Notch and PTH/PTHrP
[12,13,14]. Far less has been reported on the NFkB, MAPK
and JAK/STAT pathways. It has been postulated that NFkB
signaling may be detrimental to OB differentiation [41] whilst the
MAPKs, particularly ERK, have been reported to act upstream of
Runx2 and Osterix to increase their mRNA and protein levels but
also to enhance their transcriptional activity [42,43,44]. In view of
the strong regulation of STAT3 in our co-cultures, we assessed the
requirement for STAT3 signaling in MSC differentiation.
Adenoviruses expressing a constitutively active (STAT3C) or a
dominant negative (STAT3DN) form of STAT3 were used to
infect MSCs (Figure 3A). STAT3C led to a super-induction in
ALP activity levels compared to control adenoviral vector
(AdGFP) (Figure 3B) as well as increased formation of mineralised
bone nodules (Figure 3C), whilst little effect was seen in
STAT3DN MSCs. To validate whether the activation of STAT3
in MSCs was required for osteogenesis induced by monocytes,
STAT3C and STAT3DN infected MSCs were cultured in
monocyte/MSC co-culture supernatants. STAT3DN suppressed
ALP induction in MSC cultured with co-culture supernatants
(Figure 3D) indicating that the activation of STAT3 in MSCs is
required for the osteogenic effect of the co-culture supernatants.
The combination of STAT3 constitutive activation in MSCs and
treatment with 10:1 co-culture supernatant caused a super
induction of ALP activity (Figure 3D), further indicating that co-
culture supernatants contain other factors that can act in concert
with STAT3 for OB differentiation.
Microarray Analysis of STAT3 Activated Factors in MSCs
To elucidate the mechanisms behind the regulation of
osteogenesis by STAT3, genome-wide changes in gene expression
of MSCs infected with the STAT3 viruses or the control
adenoviral vector AdGFP were assessed using Illumina Human
HT-12 v3.0 Expression BeadChip microarrays. Prior to the
microarray analysis, it was verified by real time RT-PCR that 24
hours after infection with STAT3C was sufficient to cause a two-
fold up-regulation of ALP mRNA in MSCs (data not shown).
MSCs from five different donors were infected with the adenoviral
constructs and cultured for 24 hours after which RNA was
isolated. Raw data normalization, filtering and analysis were
performed using GeneSpring 11.5. Genes with significantly altered
expressions between STAT3C or STAT3DN and AdGFP were
identified by one way ANOVA with Benjamini-Hochberg multiple
testing correction, with p,0.01. The entities satisfying the
significance analysis were subsequently used for the fold change
analysis that is calculated by dividing the average normalised
intensity for a given gene in treated samples from the respective
control values. We identified 479 genes that were differentially
regulated between STAT3C MSC and AdGFP MSC by at least
1.5-fold, of which 314 were up-regulated and 165 down-regulated.
The top 50 genes of both groups according to highest fold changes
are listed in Tables 1 and 2, respectively. In contrast, only five
genes were differentially expressed between STAT3DN MSC and
AdGFP MSC by at least 1.5-fold. The genes differentially
regulated by STAT3C included those previously reported to be
STAT3 targets such as SOCS3 [45], lipopolysaccharide-binding
protein (LBP) [46], Jun, JunB [47], Myc [48], HIF1A [49], Pim1
[50] and VEGF [51]. Furthermore, a significant number of genes
found to be up-regulated (including LBP, IL1R1, SERPIN,
IGFBP1, CCL2, EFNA1, ANGPTL4, BCL3) or down-regulated
(including IFIT1, MX1, OAS1, MYC, PDK4) by STAT3C were
consistent with those identified to be regulated by STAT3 in lung
epithelial cells [52], indicating that these genes are not unique to
OB differentiation. In contrast, up-regulation of OSMR and
PDGFRA, also induced by STAT3C in mouse embryonic
fibroblasts [53], may be more relevant to OB differentiation of
MSC.
The genes differentially regulated in STAT3C MSC v AdGFP
MSC were classified ontologically using PANTHER classification
system pathways which also statistically determines over- or under-
representation of genes in a particular pathway (Table 3). Pathway
analysis showed significant over-representation of genes related to
inflammation mediated by chemokine and cytokine signaling
pathway including many chemokines such as CCL2, CCL3L,
CCL8 and CCL7 (Table 4), which are known to exhibit
chemoattractant activity for monocytes and macrophages. Other
significantly represented pathways were angiogenesis and inter-
leukin signalling pathways, TGF-b signalling pathway, cytoskeletal
regulation by Rho GTPase and Toll receptor signalling pathway.
In addition, each gene was researched against published literature
using PubMed to identify relations to OB differentiation and
function (Table 4). There was no significant increase in the
expression of any of the BMP or TGFb family members. There
was a significant increase in ALP as expected, as well as in the OB
transcription factor, Runx2, accompanied by a decrease in the
Wnt signalling inhibitor, Dkk1.
Oncostatin M Mediates the abIlity of Monocytes to
Increase MSC-OB Differentiation
Overexpression of STAT3C also led to the up-regulation of
OSMR (Figure 4A) and LIFR (Figure 4B) mRNA as assessed by
RT-PCR; OSM has been reported to act via both receptors to
enhance OB activity [54]. Due to the up-regulation of these
receptors, the levels of OSM produced in the monocyte/MSC co-
cultures were examined. Although OSM was not produced by
MSCs or monocytes cultured alone, its levels increased over the
course of 48 hours in monocyte/MSC co-cultures (Figure 4C).
When added to MSC cultures directly, recombinant human OSM
induced osteogenic differentiation in a dose dependent manner as
assayed by quantification of ALP activity (Figure 4D). In addition,
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Figure 2. Osteogenic induction requires cell contact and monocyte-derived soluble factors. MSCs were cultured either alone, with 10:1
monocytes in contact, with monocytes separated by a 0.4 mm pore size cell culture insert (upper chamber) or with a co-culture of 10:1 monocyte:MSC
in the cell culture insert (upper chamber), in the presence or absence of osteogenic stimuli. After 7 days, MSC ALP was assessed by staining (A) and
quantification of enzyme activity (B). ALP activity induced by 10:1 monocyte:MSC co-cultures was compared to that induced by treatment with
supernatant from co-cultures incubated for 24 hours (10:1 s/n) (C). ALP activity of MSCs was also measured after 7 days of co-culture with either fresh
of fixed monocytes (fixed in 0.05% glutaraldehyde for 1 min followed by 1 min in 0.2 M glycine) (D). MSC were treated for 30 mins with supernatant
from monocyte:MSC co-cultures or monocyte:MSC co-cultures where either monocytes or MSCs had been fixed (f), in control media (CM) or in
Monocytes Promote Osteoblast Differentiation
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MSCs cultured in the presence of OSM showed phosphorylation
of STAT3 within 10 minutes as observed by western blot
(Figure 4E). Conversely, the addition of OSM neutralizing
antibodies in MSC/monocyte co-cultures abrogated the ALP
induction in a dose dependent manner verifying OSM as a
monocyte-derived factor with osteogenic activity (Figure 4F). The
ability of OSM to stimulate bone formation in vivo was assessed by
injecting mOSM over calvariae of 5-week-old male C57BL/6
mice. Calvarial thickness, inter-label width (Ir.L.W.) and mineral
apposition rate (M.A.R.) were all significantly increased by mOSM
treatment compared to PBS (Figure 4G–J). Thus, OSM produced
after monocyte/MSC interactions is responsible for increased
osteogenesis through the activation of STAT3 signaling which in
addition acts as positive feedback to enhance the effects of OSM
on MSCs by up-regulating the OSM and LIF receptors.
Discussion
Previously there has been limited evidence regarding the direct
regulation of OB differentiation by immune cells. Earlier studies
suggested a possible role for activated T cells in influencing OB
differentiation through soluble factors [55,56], and haematopoietic
stem cells have also been shown to regulate OB differentiation
through the production of BMP2 and BMP6 [57]. More recently,
resident macrophage populations found in bone have been
demonstrated to serve as critical regulators of bone homeostasis
osteogenic media (OM) and then lysed (E). MSCs alone in CM and OM were used as controls. MSC lysates (10 mg per condition) were subjected to WB
for detection of IkBa, p-p38, pERKs, p-JNKs and pSTAT3. Anti-b-Tubulin was used as a loading control. The levels of IL-1b, IL-10, TNFa, IL-6, IL6R and IL-
8 were measured in culture media from MSC or monocyte alone cultures or 10:1 monocyte:MSC co-cultures (F). Phase contrast pictures (10X) are
representative of three independent experiments performed. Graphs show means 6 SEM of at least three independent experiments performed in
triplicate. *p#0.05, **p#0.01, ***p#0.001 Blots are representative of three independent experiments performed.
doi:10.1371/journal.pone.0039871.g002
Figure 3. OSMmediates monocyte osteogenic effect through STAT3 signaling. The levels of pSTAT3 and STAT3 were assessed using WB in
MSCs infected either with STAT3C (50 M.O.I.) or STAT3DN (100 M.O.I.) adenoviruses in osteogenic media. GFP adenoviral infection was used as a
control (100 M.O.I.) (A). MSC ALP activity was measured 7 days after infection either with STAT3DN, STAT3C or AdGFP (B). MSC infected with the
STAT3C or AdGFP viruses were also kept for 21 days in osteogenic media when bone nodule formation was assessed using Alizarin Red S staining (C).
MSC infected with either the STAT3DN, STAT3C or AdGFP were kept with or without conditioned supernatant from separate monocyte:MSC co-
cultures (10:1 s/n) for 7 days when ALP activity was quantified (D). Blots are representative of three independent experiments performed. Graphs
show means 6 SEM of three independent experiments performed in triplicate. Phase contrast pictures (10X) are representative of three independent
experiments performed. *p#0.05, ***p#0.001.
doi:10.1371/journal.pone.0039871.g003
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Table 1. Genes up-regulated by STATC.
Symbol Definition
Fold change STAT3C v
AdGFP
LBP Lipopolysaccharide binding protein 10.31
IL1RL1 Interleukin 1 receptor-like 1 9.95
SAA2 Serum amyloid A2 8.37
CCL8 Chemokine (C-C motif) ligand 8 7.98
NFE2 Nuclear factor (erythroid-derived 2) 6.67
SERPINB4 Serpin peptidase inhibitor clade B (ovalbumin), member 4 5.99
PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 5.67
F3 Coagulation factor III (thromboplastin, tissue factor) 5.18
EFNA1 Ephrin A1 4.96
IL6 Interleukin 6 (interferon, beta 2) 4.92
CHI3L2 Chitinase 3-like 2 4.55
SOCS3 Suppressor of cytokine signaling 3 4.55
SAA1 Serum amyloid A1 4.43
FLJ22447 PREDICTED: hypothetical gene supported by AK026100 4.42
WWC1 WW and C2 domain containing 1 4.33
SERPINB3 Serpin peptidase inhibitor clade B (ovalbumin), member 3 4.27
NAMPT Nicotinamide phosphoribosyltransferase 4.25
MT1M Metallothionein 1 M 4.22
CH25H Cholesterol 25-hydroxylase 4.08
PIM1 pim-1 oncogene 4.07
STEAP4 STEAP family member 4 3.76
KIAA1199 KIAA1199 3.68
CA2 Carbonic anhydrase II 3.65
TNC Tenascin C 3.58
ANGPTL4 Angiopoietin-like 4 3.39
RCAN1 Regulator of calcineurin 1 3.39
ACHE Acetylcholinesterase 3.38
HP Haptoglobin 3.33
GSDMC Gasdermin C 3.27
IL1R2 Interleukin 1 receptor, type II 3.22
BCL3 B-cell CLL/lymphoma 3 3.18
IL1R1 Interleukin 1 receptor, type I 3.03
RGS16 Regulator of G-protein signaling 16 3
MAFB v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) 2.99
TDO2 Tryptophan 2,3-dioxygenase (TDO2) 2.93
KRTAP1–5 Keratin associated protein 1–5 2.92
SLC2A3 Solute carrier family 2 (facilitated glucose transporter), member 3 2.92
PLAU Plasminogen activator, urokinase 2.90
C10orf10 Chromosome 10 open reading frame 10 2.90
IGF1 Insulin-like growth factor 1 (somatomedin C) 2.87
GLDN Gliomedin 2.83
G0S2 G0/G1switch 2 2.83
TNFRSF21 Tumor necrosis factor receptor superfamily, member 21 2.82
SERPINA3 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 2.78
CXCL5 Chemokine (C-X-C motif) ligand 5 2.76
MT1X Metallothionein 1X 2.74
STEAP1 PREDICTED: Six transmembrane epithelial antigen of the prostate 1 2.74
CCL7 Chemokine (C-C motif) ligand 7 (CCL7) 2.69
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[25] as well as repair in a murine tibia injury model [26].
However, the mechanisms and mediators of these important
interactions remain elusive. These studies proposed that the close
interactions between OBs and macrophages in vivo are critical for
the integrity of bone remodelling sites as well as efficient
mineralization. In this study, we show that monocytes and
macrophages directly regulate osteogenic differentiation of MSCs
through a mechanism that involves cell contact, leading to the
production of OSM by monocytes and STAT3 signalling in the
MSCs.
In support of our findings, Guihard and colleagues have
recently shown that monocyte-macrophage production of OSM
upon toll-like receptor (TLR) activation by liposaccharide or
endogenous ligands such as poly I:C, can promote osteogenesis
[58]. However, by specifically focusing on the responses in the
context of activated monocytes and macrophages, their findings
are only relevant to pathological settings such as bone inflamma-
tion, infection or injury. We find that it is the contact between
monocytes and MSC that regulates the production of OSM by the
monocytes and the up-regulation of the OSM and LIF receptors
on the MSC. The use of non-activated monocytes and macro-
phages in our system makes our findings more relevant to the
regulatory networks governing physiological bone formation and
provide further evidence of the crucial role of monocyte/
macrophages and their derived factors in these networks.
A number of cytokines including IL-1b, IL-10, IL-6 and TNFa
were increased following contact between MSC and monocytes in
agreement with previous studies [35,37,38,59,60], however these
were not responsible for the enhanced osteogenesis induced by
monocytes. Although some studies have identified a role for IL-6
in directly promoting osteogenic differentiation [61,62], these were
conducted on osteoblastic cell lines such as MG-63 or calvarial
OBs. Additionally, the induction of STAT3 in co-cultures of
MSCs with macrophages has also been previously reported
suggesting that this could be a mechanism by which MSCs
promote an anti-inflammatory phenotype in macrophages [63].
However, as we show here, the activation of STAT3 signaling in
the MSCs in co-cultures cannot be attributable to the up-
regulation of IL-10 or IL-6 since both cytokines failed to induce
STAT3 phosphorylation in MSCs.
Signalling through the JAK/STAT pathway has previously
been shown to be important for OB differentiation. OB-specific
disruption of the Stat3 gene via the Cre-LoxP recombination
system using a1(I)-collagen promoter Cre transgenic mice results
in a reduced rate of bone formation, leading to an osteoporotic
phenotype while glycoprotein 130 (gp130) knock-in mice, in which
STAT3 activation is enhanced, exhibit an osteosclerotic pheno-
type [64]. Thus STAT3 signaling in OBs plays a pivotal role in
bone formation in vivo. In our system, the role of STAT3 signaling
in mediating the osteogenic effects of monocytes was validated by
the enhanced osteogenesis observed in MSCs overexpressing
STAT3C and by the ability of a STAT3 DN virus to suppress
MSC ALP activity induced by the osteogenic 10:1 co-culture
supernatants (Figure 3). These findings confirm that monocyte/
macrophage-induced MSC osteogenesis occurs via the STAT3
signaling pathway and are consistent with a recent study which
showed that the siRNA knockdown of STAT3 resulted in a
significant reduction of MSC ALP activity following treatment
with dexamethasone and BMP-2 [65]. By contrast, however, in a
separate study eradication of STAT3 signalling also using siRNA
has been found to result in highly efficient osteogenic differenti-
ation induced by BMP-2 albeit also showing that BMP2/4
induced STAT3 tyrosine phosphorylation [66]. In spite of these
contradictory findings, the majority of published literature as well
as our investigations stipulate an important role for STAT3
signaling positively influencing MSC osteogenic differentiation.
Importantly a great number of genes known to be associated
with OB differentiation were identified to be induced by STAT3C
in our microarray screening. As expected, ALP was shown to be
up-regulated by 2.6 fold in MSC STAT3C compared to MSC
AdGFP. Furthermore, the bone-specific transcription factor
Runx2 expression was up-regulated by 1.95 fold in STAT3C
MSC. In contrast, expression of Dkk1, a negative regulator of Wnt
signaling and osteogenic differentiation [18,67], was down-
regulated by 2.28 fold in STAT3C MSC. These observations
suggest that the overall balance is strongly in favour of OB
differentiation. Furthermore, the rapid increase in both Runx2
and ALP suggests that these two genes are direct targets of STAT3
although further studies are required to test this hypothesis.
Interestingly, both IGF1, which is known to promote osteogenic
differentiation [68] as well as mediate other anabolic effects, and
IGF binding protein 1 (IGFBP1) were also found to be up-
regulated. Serum amyloid A2 and A1 were up-regulated in the
STAT3C MSC yet SAA2 was down-regulated 1.56 fold in the
STAT3DN MSC. Serum amyloid A (SAA) proteins are a family of
cytokine-induced acute-phase proteins that participate in the acute
inflammatory process through the recruitment of immune cells
and the induction of enzymes that degrade extracellular matrix.
Expression of SAA1/2 has been demonstrated in non-differenti-
ated MSCs and was shown to increase during osteogenic
differentiation [69]. EphrinA1, the ligand receptor for EphA2 a
membrane bound receptor tyrosine kinase [70], was up-regulated
by STAT3C. Recent studies suggest that Eph/eprhin molecules
regulate bone homeostasis mediating the crosstalk between OBs
and OCs. More specifically, bidirectional signaling through ephrin
A2-EphA2 was shown to enhance osteoclastogenesis while
suppressing osteoblastogenesis [71], while recently ephrin B
molecules were shown to be required for mineralisation and
glycosaminoglycan synthesis in in vitro MSC cultures [72]. These
findings may suggest a role for ephrinA1 in regulating osteogen-
esis.
STAT3C induced the expression of OSMR and LIFR (by 2 fold
and 1.66 fold respectively) which together with gp130 form
receptor complexes for OSM. OSM belongs to the IL-6 family of
Table 1. Cont.
Symbol Definition
Fold change STAT3C v
AdGFP
INSIG1 Insulin induced gene 1 2.68
NOD1 Nucleotide-binding oligomerization domain containing 1 2.64
The table lists the 50 most highly significantly up-regulated transcripts in MSC STAT3C compared to MSC AdGFP (with p,0.01 cutoff using one way ANOVA with
Benjamini-Hochberg multiple testing correction). Values shown are the medians from the five donors.
doi:10.1371/journal.pone.0039871.t001
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Table 2. Genes down-regulated by STATC.
Symbol Definition
Fold change STAT3C
v AdGFP
KRTAP1–5 Keratin associated protein 1–5 22.92
IFIT1 Interferon-induced protein with tetratricopeptide repeats 1 22.68
C10orf54 Chromosome 10 open reading frame 54 22.68
LOC728956 PREDICTED: Similar to keratin associated protein 1.5 22.63
LOC728946 PREDICTED: Similar to keratin associated protein 1-1 22.49
FAM43A Family with sequence similarity 43, member A 22.41
PGBD3 PiggyBac transposable element derived 3 22.37
LOC728951 PREDICTED: Similar to keratin associated protein 1–3 22.32
MARCH4 Membrane-associated ring finger (C3HC4) 4 22.29
DKK1 Dickkopf homolog 1 (Xenopus laevis) 22.28
ADH1A Alcohol dehydrogenase 1A (class I), alpha polypeptide 22.28
OSAP Ovary-specific acidic protein 22.18
RGS4 Regulator of G-protein signalling 4 22.17
CTNNB1 Catenin (cadherin-associated protein), beta 1, 88 kDa 22.13
DUSP10 Dual specificity phosphatase 10 22.13
ADRA1B Adrenergic, alpha-1B-, receptor 22.13
PPP1R3C Protein phosphatase 1, regulatory (inhibitor) subunit 3C 22.12
SORBS2 Sorbin and SH3 domain containing 2 22.12
C4orf49 Chromosome 4 open reading frame 49 22.11
PDK4 Pyruvate dehydrogenase kinase, isozyme 4 22.10
TNFRSF19 Tumor necrosis factor receptor superfamily, member 19 22.08
SLC40A1 Solute carrier family 40 (iron-regulated transporter), member 1 22.05
CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 22.05
CPA4 Carboxypeptidase A4 22.04
LRRN3 Leucine rich repeat neuronal 3, transcript variant 1 22.01
CLIC3 Chloride intracellular channel 3 21.97
ARPC2 Actin related protein 2/3 complex, subunit 2, 34 kDa 21.97
ANGPT1 Angiopoietin 1 21.93
NR2F1 Nuclear receptor subfamily 2, group F, member 1 21.93
EDN1 Endothelin 1 21.92
IRX5 Iroquois homeobox protein 5 21.92
CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain 2 21.92
LYPD6B LY6/PLAUR domain containing 6 B 21.91
UNQ1940 HWKM1940 21.90
K-EST0187371 L5HLK1 Homo sapiens cDNA clone L5HLK1-32-B12 5 21.89
MEOX2 Mesenchyme homeobox 2 21.89
STC2 Stanniocalcin 2 21.88
TSC22D3 TSC22 domain family, member 3 21.87
PIK3IP1 Phosphoinositide-3-kinase interacting protein 1 21.87
EBF3 Early B-cell factor 3 21.86
FHL1 Four and a half LIM domains 1 21.86
EFHD1 EF-hand domain family, member D1 21.85
DHRS3 Dehydrogenase/reductase (SDR family) member 3 21.84
ERCC6 Excision repair cross-complementing rodent repair deficiency, complementation group 6 21.81
TXNRD1 Thioredoxin reductase 1 21.80
TIAM2 T-cell lymphoma invasion and metastasis 2 21.79
KCTD12 Potassium channel tetramerisation domain containing 12 21.78
TMEM47 Transmembrane protein 47 21.78
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cytokines which signal primarily through JAK/STAT3 but also
MAPKs pathways. OSM signaling through gp130 and STAT3 has
been linked to OB differentiation [73]. Receptor components
gp130, LIFR and OSMR that bind OSM are expressed by bone
marrow osteoblastic cells, OB cell lines as well as mouse calvaria
OBs, bone lining cells and osteocytes [54,74]. In support of our
findings, OSM can promote osteogenic differentiation and
mineralisation both in vitro and in vivo whilst IL-6 and LIF did
not induce mineralisation [54,75,76,77]. Transgenic mice overex-
pressing OSM develop osteopetrotic bones and enlarged hind
limbs, likely by stimulation of bone formation and concomitant
inhibition of bone resorption [78]. In addition, monocytes and
macrophages are known producers of OSM [79] and it has been
shown that PGE2 can induce OSM expression in microglia, the
resident macrophages of the brain, as well as in monocytes and
macrophages of mouse and human origin [80]. Similar to the
induction of STAT3 signaling in MSCs shown here, OSM can
activate STAT3 in OBs [81]. Stimulation of ALP activity by OSM
was abrogated by tyrosine kinase inhibitors as well as a threonine/
serine kinase inhibitor, but only minimally affected by a specific
inhibitor of MAPK phosphorylation, indicating a primary role for
the JAK/STAT pathways mediating OSM osteogenic properties
[61]. OSM signalling through STAT3 has also been shown to
directly target Wnt5a [82,83] which promotes osteogenic differ-
entiation of MSCs.
Following the identification of OSM as an important mediator
of OB regulation by monocytes and macrophages, it would be
pertinent to investigate the expression of OSM in the distinct
macrophage population, termed Osteomacs, found to be interca-
lated throughout bone tissues and specifically located adjacent to
the layer of bone lining cells [25]. Indeed, Walker and colleagues
have recently described that OSM is expressed throughout murine
bone tissue where it regulates OBs acting through both the OSMR
and LIFR with distinct outcomes [54]. More specifically, signaling
Table 2. Cont.
Symbol Definition
Fold change STAT3C
v AdGFP
IFIT2 Interferon-induced protein with tetratricopeptide repeats 2 21.77
ADH1B Alcohol dehydrogenase IB (class I), beta polypeptide 21.76
The table lists the 50 most highly significantly down-regulated transcripts in MSC STAT3C compared to MSC AdGFP (with p,0.01 cutoff using one way ANOVA with
Benjamini-Hochberg multiple testing correction). Values shown are the medians from the five donors.
doi:10.1371/journal.pone.0039871.t002
Table 3. Pathways identified by ontological analysis to be over-represented in MSC STAT3C versus MSC AdGFP.
Pathways
Homo sapiens
genes
Regulated genes 1.5 fold
STAT3C v AdGFP Expected P value
Inflammation mediated by chemokine and
cytokine signaling pathway
283 23 6.21 1.33E207
Angiogenesis 191 12 4.19 1.27E203
Unclassified 17337 362 380.51 6.54E203
Plasminogen activating cascade 18 3 0.4 7.63E203
Insulin/IGF pathway-mitogen activated protein
kinase kinase/MAP kinase cascade
35 4 0.77 7.84E203
Interleukin signaling pathway 161 9 3.53 1.01E202
Oxidative stress response 60 5 1.32 1.11E202
Alzheimer disease-presenilin pathway 122 7 2.68 1.94E202
Blood coagulation 48 4 1.05 2.23E202
Cytoskeletal regulation by Rho GTPase 98 6 2.15 2.23E202
Interferon-gamma signaling pathway 29 3 0.64 2.68E202
Heterotrimeric G-protein signaling pathway-Gq
alpha and Go alpha mediated pathway
134 7 2.94 3.01E202
Ras Pathway 79 5 1.73 3.15E202
TGF-beta signaling pathway 145 7 3.18 4.29E202
Threonine biosynthesis 2 1 0.04 4.29E202
Lysine biosynthesis 2 1 0.04 4.29E202
Carnitine metabolism 2 1 0.04 4.29E202
Carnitine and CoA metabolism 2 1 0.04 4.29E202
FAS signaling pathway 36 3 0.79 4.59E202
Toll receptor signaling pathway 62 4 1.36 4.91E202
Pathways identified by ontological analysis to be significantly overrepresented in the differentially regulated genes of the STAT3C MSCs versus AdGFP MSCs analysis.
doi:10.1371/journal.pone.0039871.t003
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through the OSMR was associated with early stromal cell lineage
commitment towards OBs through up-regulation of C/EBPb and
C/EBPd whereas OSM action through LIFR was associated with
inhibition of sclerostin expression in osteocytes.
In conclusion, we show that monocytes/macrophages can
potently induce the osteogenic differentiation of human MSCs in a
mechanism that involves the production of OSM by the former
that activates STAT3 in the latter. The phosphorylation of
STAT3 in the MSCs up-regulates RUNX2 and ALP expression,
along with other OB-associated genes, and down-regulates Dkk1
leading to the differentiation of MSC into OB. Additionally,
STAT3 activation in the MSCs leads to the up-regulation of
OSMR and LIFR, thereby amplifying the effects of OSM.
Methods
Cell Culture and Reagents
Adult human MSCs were commercially purchased (Product No
PT-2501, Lonza Group, Basel, Switzerland) or were isolated from
bone marrow aspirates. This study has been approved by the
National Research Ethics Service - Riverside Research Ethics
Committee (REC Ref. No. 07/H0706/81) for the study of
molecular mechanisms and pathways of chronic inflammatory
and degenerative diseases. Human samples used in this study were
obtained with written informed consent. Samples were collected at
the time of musculoskeletal surgery for joint replacement or
following traumatic injury.
MSCs were maintained in DMEM Glutamax media supple-
mented with 10% FBS (PAA, Austria) and 1% penicillin/
streptomycin (PAA, Austria) and used between passage 3 and 8.
Prior to their use in experiments MSCs were verified for their
plastic-adherence, expression of cell surface markers CD105,
CD73 and CD90 but lack of CD45, CD34 and HLA-DR
molecules as well as tri-lineage differentiation to osteoblasts,
adipocytes and chondrocytes in the presence of standard
differentiation cocktails in vitro. Peripheral blood mononuclear
cells (PBMC) were prepared from buffy coat fractions (North
London Blood Service, Colindale, UK) by density gradient
Table 4. Selected genes associated with OB differentiation and/or function.
Symbol Definition
Fold change STAT3C
v AdGFP References
SAA2 Serum amyloid A2 8.37 [69]
EFNA1 Ephrin A1 4.97 [72,87]
IL6 Interleukin 6 4.92 [88]
SAA1 Serum amyloid A1 4.43 [69]
MT1M Metallothionein 1 M 4.22 [89]
TNC Tenascin C 3.58 [90]
RCAN1 Regulator of calcineurin 1 3.39 [91]
IL1R2 Interleukin 1 receptor, type II 3.23 [92]
IL1R1 Interleukin 1 receptor, type I 3.04 [92]
RGS16 Regulator of G-protein signalling 16 3.00 [88]
PLAU Plasminogen activator, urokinase 2.90 [93]
IGF1 Insulin-like growth factor 1 2.87 [68,94]
CXCL5 Chemokine (C-X-C motif) ligand 5 2.76 [95]
MT1X Metallothionein 1X 2.73 [89]
CCL7 Chemokine (C-C motif) ligand 7 2.67 [88]
ALPL Alkaline phosphatase, liver/bone/kidney 2.60 [96]
RGS2 Regulator of G-protein signalling 2 2.57 [88]
DKK1 Dickkopf homolog 1 (Xenopus laevis) 22.28 [97]
IGFBP1 Insulin-like growth factor binding protein 1 2.27 [98]
MT1H Metallothionein 1 H 2.24 [89]
RGS4 Regulator of G-protein signalling 4 22.17 [88]
OSMR Oncostatin M receptor 2.05 [54]
CCL2 Chemokine (C-C motif) ligand 2 2.03 [95]
RUNX2 Runt-related transcription factor 2 1.95 [99]
MTE Metallothionein E 1.76 [89]
PDGFRA Platelet-derived growth factor receptor-alpha 1.76 [100]
MT1E Metallothionein 1 E 1.67 [89]
MT1G Metallothionein 1 G 1.67 [89]
LIFR Leukemia inhibitory factor receptor alpha 1.66 [54]
IL24 Interleukin 24 1.50 [88]
Differentially regulated transcripts in MSC STAT3C compared to MSC AdGFP associated with osteogenic differentiation and function.
doi:10.1371/journal.pone.0039871.t004
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centrifugation. Depletion and enrichment of T cells, B cells and
monocytes was performed using CD3, CD19 and CD14
Dynabeads and negative selection kits respectively (DynalH T cell
Negative Isolation Kit Ver II for T cells, DynalH B Cell Negative
Isolation Kit for B cells and DynabeadsH MyPureTM Monocyte
Kit 2 for monocytes) all from Invitrogen, according to manufac-
turer’s instructions. Recombinant IL-1b, IL-6, IL-8, TNFa, IL-10
and OSM were purchased from Peprotech and all corresponding
neutralising antibodies were from R&D systems. For real-time
reverse transcription PCR Inventoried TaqManH Gene expression
Figure 4. OSM mediates monocyte osteogenic effect. RNA was isolated from STAT3C, STAT3DN and AdGFP infected MSC after 24 h of
infection and the levels of OSMR (A) and LIFR (B) mRNA were measured using real-time RT-PCR. Graphs are expressed as fold induction compared to
AdGFP infected MSC. OSM levels were assessed in supernatants from either MSCs or monocytes cultured alone or MSC/monocytes co-cultured for
4 h, 8 h, 24 h and 48 h using OSM ELISA (C). MSC (16104) were treated with increasing concentration of human recombinant OSM in either control or
osteogenic media and ALP activity was assessed after 7 days (D). MSCs were treated with 10 ng/ml of OSM for increasing time (10, 20, 30 and
60 mins), cultures were lysed and 10 mg of protein per condition was subjected to WB for detection of pSTAT3, STAT3 and b-tubulin (E). OSM
neutralising antibody was added to MSC:monocyte co-cultures at increasing concentration (10, 100, 1000 and 10000 ng/ml) in control or osteogenic
media. Isotype control was also added to match the highest concentration. ALP activity was quantified after 7 days (F). Blots are representative of
three independent experiments performed. Graphs show means 6 SEM of at least three independent experiments performed in triplicate. *p#0.05
***p#0.001. Calcein labeled calvaria sections from mice injected daily with either recombinant murine OSM or PBS observed under fluorescent light
(20X) (G). Local administration of 0.2 mg/d mOSM for 5 days in C57BL/6 mice significantly increased calvarial thickness (H), inter-label width (Ir.L.W.) (I)
and mineral apposition rate (MAR) (J). Data are shown as mean + SEM, 6 mice/group.
doi:10.1371/journal.pone.0039871.g004
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Assays for OSMR (Hs00384278_m1) and LIFR
(Hs01123581_m1) were used (Applied Biosystems) with Reverse
Transcriptase qPCRTM Mastermix No ROX (Eurogentec). All
other reagents were purchased from Sigma-Aldrich unless
otherwise stated.
MSC Differentiation
MSCs were cultured in osteogenic medium: D-MEM Glutamax
supplemented with 100 nM dexamethasone, 50 mg/ml ascorbic
acid 2-phosphate and 10 mM b-glycerophosphate. After 7 days,
cells were either fixed with acetone:ethanol and stained for ALP
using Sigma FASTTM BCIP/NBT tablet (Sigma-Aldrich) or their
ALP activity was determined using LabAssayTM ALP kit (Wako,
Japan). Bone nodule formation was assessed at 21 days by alizarin
red S staining and quantification of dye content [84].
Western Blot
Cell lysates were prepared in lysis buffer (25 mM HEPES
(pH 7.0), 150 mM NaCl, and 1% Nonidet P-40), containing
protease inhibitor cocktail (Roche Biochemicals, USA), and then
electrophoresed on 10% SDS polyacrylamide gels, followed by
electrotransfer of proteins onto PVDF transfer membranes
(Perkin Elmer Life Sciences Inc., USA). Membranes were
blocked in 8% non-fat dry milk/PBS (0.05%)/Tween and
incubated overnight at 4uC with polyclonal primary antibodies
against pSTAT3 (Tyr705), p-p38, pERKs, pJNKs (all from Cell
Signaling Technology), STAT3, IkBa (both from Santa Cruz) or
b-tubulin (Sigma-Aldrich). Horseradish peroxidase-conjugated
anti-mouse IgG or anti-rabbit IgG (Amersham Biosciences) were
used as secondary antibodies at a dilution of 1:2000. Bound
antibody was detected using the enhanced chemiluminescence kit
(Amersham Biosciences) and visualized using Hyperfilm MP
(Amersham Biosciences).
ELISA
The levels of various cytokines in culture supernatants were
measured using a Human Cytokine 30-plex Luminex assay kit
(Invitrogen). OSM levels were measured using the Human OSM
DuoSet from R&D systems.
Adenoviral Infection
Recombinant adenoviruses expressing STAT3 constitutively
active (C; A661C and N663C), STAT3 dominant negative (DN;
Y705F) and green fluorescent protein (GFP) were used to infect
MSC [85,86]. Adenoviral infection efficiency was assessed by
western blotting.
Microarray
The microarray study was performed using the HumanHT-12
v3 expression BeadChips on the Illumina Whole-Genome Gene
Expression analysis platform. MSCs from five different donors
were infected with STAT3C, STAT3DN or AdGFP adenoviral
constructs as described above and independent chips were used for
each donor. Total RNA was extracted from each sample using the
QIAamp RNA Blood Mini Kit (Qiagen Ltd, Crawley, West
Sussex, UK) according to manufacturer’s instructions. Isolated
RNA was quantified and RNA quality assessed using the
RNA6000 Nano Assay on Agilent BioAnalyzer 2100 (Agilent
Technologies, Santa Clara, CA). Commercially available high-
density oligonucleotide, from Illumina whole genome gene
expression BeadChips (Human HT12_V3_0_R3_11283641, Illu-
mina Inc, San Diego, California, USA), were used with 48803
probes representing 37879 human transcripts. In brief, total RNAs
were reverse transcribed to synthesize first- and second- strand
complementary DNA (cDNA), followed by in vitro transcription to
synthesize biotin-labeled complementary RNA (cRNA) using
TotalPrep-96 RNA amplification kit (Ambion). A total of 750 ng
of biotin-labeled cRNA from each sample was hybridised to the
HT12 BeadChip (Illumina Inc., San Diego, CA) at 58uC for 18
hours. The hybridised BeadChips were washed and labeled with
streptavidin-Cy3 and then scanned with Illumina BeadScan and
images imported into GenomeStudioV2010.1 (Illumina Inc) for
data extraction. Data were normalised and analysed using
GeneSpring 11.5 (Agilent Technologies, Santa Clara, CA).
Microarray data were normalised by percentile shift to the 75th
percentile with the baseline set to the median of all samples. Genes
with low expression (20% or less above background noise) were
filtered out from further analysis. The data presented here is
MIAME compliant.
In Vivo OSM Administration
Recombinant murine OSM (R&D systems) was administered
to 5-wk-old male C57/Bl6 mice by calvarial injections. Briefly,
mice were injected daily with 0.2 mg mOSM or PBS over the
left hemicalvaria for 5 consecutive days. Calcein (20 mg/kg) was
injected intraperitoneally on days 1 and 14. Parietal bones were
collected 24 hours after the last injection, fixed, embedded in
methyl methacrylate resin and sections were analyzed by
histomorphometry using the Osteomeasure software (Osteomea-
sure, Osteometrics). All animal procedures were conducted
under Home Office project licence PPL70/7335.
Statistical Analysis
Data are presented as the mean and standard error of the mean
(S.E.M.) of at least three independent experiments performed in
triplicate. Statistical analysis was performed on GraphPad Prism
version 5 (GraphPad software, San Diego, CA) using one way
analysis of variance (ANOVA) with Bonferroni’s correction for
multiple comparisons or alternatively Dunnett’s post-test correc-
tion where multiple results were compared against a standard or
control series. Significant results were depicted using asterisks,
where *: P,0.05, **: P,0.01, ***: P,0.001. Genes with
significantly altered expressions were identified by one way
ANOVA with Benjamini-Hochberg multiple testing correction,
with p,0.01. The entities satisfying the significance analysis were
passed on for the fold change analysis. For a given gene its change
in expression was calculated by dividing its average normalised
intensity in treated samples from the respective control values.
Significantly differentially expressed genes were identified with
functional classifications, pathways analysis and gene set enrich-
ment determined.
Supporting Information
Figure S1 Monocyte osteogenic effect is not mediated
by monocyte-derived cytokines. ALP activity of MSCs was
measured after treatment with increasing concentrations of human
recombinant IL1b in control and osteogenic media (A), or in the
presence of neutralising antibody to inhibit endogenous IL1b in
MSC-macrophage (Mw) co-cultures (B). ALP activity of MSC was
also measured after treatment with increasing concentrations of
human recombinant TNFa (C) or IL8 (D), IL10 (E) and IL6 (G).
Lysates (10 mg of protein) from MSCs treated with either human
recombinant IL10 (F) or IL6 (I) at increasing concentrations or for
increasing duration were subjected to WB for detection of
pSTAT3 and STAT3. Graphs show means 6 SEM of three
independent experiments performed in triplicate. Blots are
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representative of three independent experiments performed.
*p#0.05 ***p#0.001.
(TIF)
Figure S2 Monocyte osteogenic effect is not mediated
by BMPs or TGFb. MSC-macrophage (Mw) co-cultures (ratio
1:10) were established in the presence of neutralizing antibodies
against BMP2/4, BMP3, BMP7 and TGFb at 10 mg/ml as well as
IgG1 and IgG2B isotype controls and ALP activity quantified after
7 days. Graphs show means 6 SEM of three independent
experiments performed in triplicate.
(TIF)
Table S1 Supernatant from MSC alone cultures and
10:1 monocyte/MSC co-culture were tested for the
presence of BMP2, BMP4, BMP7 and TGFb1 using
individual, commercially available enzyme-linked im-
munosorbent assays (all from R&D systems, Abington,
UK) according to manufacturer’s instructions. Assay
sensitivity was defined as the lowest standard for each assays’
standard curve and expressed as ‘less than’ value at, or beyond the
limit of sensitivity.
(DOCX)
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